Dinoprostone is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour. It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts. As a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour.
For the termination of pregnancy during the second trimester (from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period), as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period. Also used in the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole). Other indications include improving the cervical inducibility (cervical "ripening") in pregnant women at or near term with a medical or obstetrical need for labor induction, and the management of postpartum hemorrhage.
ElShatby University Maternal Hospital, Alexandria, Egypt
Hospital Universitario 12 de Octubre, Madrid, Spain
Hospital Clinic i Provincial, Barcelona, Spain
Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
Beni-suef university, Banī Suwayf, Egypt
UKM Medical Centre, Kuala Lumpur, W.Persekutuan, Malaysia
UKM Medical Center, Kuala Lumpur, W.Persekutuan, Malaysia
Hanoi Obstetrics and Gynecology Hospital, Hanoi, Hà Nội, Vietnam
Rambam health care campus, Haifa, Israel
Aswan University Hospital, Aswan, Egypt
University Hospital of Martinique, Fort-de-France, Martinique
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.